Clinical Research Directory
Browse clinical research sites, groups, and studies.
Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
Sponsor: Groupe Hospitalier Diaconesses Croix Saint-Simon
Summary
CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
Official title: Randomized Study Assessing Two Strategies of First Line: a Strategy With Intraperitoneal Chemotherapy and a Strategy With Total Intravenous Strategy, in Patients With Epithelial Advanced Ovarian Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2016-10
Completion Date
2032-10
Last Updated
2021-02-11
Healthy Volunteers
No
Conditions
Interventions
CC0 - Carboplatin (IV) - Paclitaxel (IV)
(6 cycles)
CC0 - Cisplatin (IP) - Epirubicin (IV)
(6 cycles)
CC>0 - Carboplatin (IV)- Paclitaxel (IV)
* carboplatin (IV) - paclitaxel (IV) (3 cycles) * Interval surgery * Carboplatin (IV) - paclitaxel (IV) (3 cycles)
CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)
* Cisplatin (IV) - Epirubicin (IV) (3 cycles) * Interval surgery : * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles) * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)
Locations (7)
Centre Georges François Leclerc
Dijon, France
Institut Hospitalier Franco-Britannique
Levallois-Perret, France
Groupe Hospitalier Diaconesses Croix Saint Simon
Paris, France
Hôpital Saint Antoine
Paris, France
Hôpital Poissy Saint Germain
Poissy, France
CHU Poitiers
Poitiers, France
Centre Hospitalier Senlis
Senlis, France